Oncotalks hematology videos and news

OÄ Sonja Heibl, MD; Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis

OÄ Sonja Heibl, MD from the Klinikum Wels-Grieskirchen, Wels, Austria is commenting on the abstract: Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

Blood (2019) 134 (Supplement_1): 669.

https://doi.org/10.1182/blood-2019-127445

Related items

Moshe Mittelman, MD, PhD; Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3)​

Moshe Mittelman, MD, PhD; Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3)​

Moshe Mittelman, MD, PhD from the Tel Aviv University, Tel Aviv, Israel is commenting on the abstract: Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3)Blood (2019) 134 (Supplement_1): 3740.https://doi.org/10.1182/blood-2019-130309
ASH , Latvia , Lithuania , Estonia , Albania
00:07:06
ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

Valentina Guarneri, MD, PhD from the University of Padua, Padua, Italy is commenting on the abstract: LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
ESMO , Kisqali Channel , Latvia , Lithuania , Estonia , Hungary , Albania
00:03:29
Sophie Servais, MD; Multipotent Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation:a Multicenter Prospective Study

Sophie Servais, MD; Multipotent Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation:a Multicenter Prospective Study

Sophie Servais, MD from the Université de Liège, Liège, Belgium is commenting on the abstract: Multipotent Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation:a Multicenter Prospective StudyBlood (2019) 134 (Supplement_1): 37.https://doi.org/10.1182/blood-2019-129992
ASH , Lithuania , Albania
00:03:30